Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Myeloid, Acute 1Gastrointestinal Stromal Tumors 1

Interventions

venetoclax 190Azacitidine 162Cytarabine 127fludarabine 97Cyclophosphamide 75Specimen Handling 68fludarabine phosphate 56Daunorubicin 53Biopsy 49Decitabine 48Whole-Body Irradiation 42Mycophenolic Acid 40Idarubicin 40Busulfan 37Injections 36Tacrolimus 35Granulocyte Colony-Stimulating Factor 35Melphalan 32Stem Cell Transplantation 30gilteritinib 25Filgrastim 25CPX-351 25decitabine and cedazuridine drug combination 23Peripheral Blood Stem Cell Transplantation 22Etoposide 20ivosidenib 19Mitoxantrone 19Cladribine 19Thiotepa 17Sirolimus 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × olverembatinib × 1 year × Clear all
NCT04501120 2026-04-29

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Ascentage Pharma Group Inc.

Phase 1/2 Recruiting
682 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡